The lawsuit claims the Company failed to disclose major safety-related updates to its RP-A501 clinical trial, including the use of an immunomodulatory agent, prior to a fatal adverse event and FDA-imposed clinical hold. After the Company publicly confirmed the trial hold and patient death on May 28, 2025, RCKT shares fell sharply dropping from $6.27 to $2.33.